Xilio Therapeutics (XLO) Share-based Compensation (2020 - 2026)

Xilio Therapeutics has disclosed Share-based Compensation across 7 years of filings, most recently posting $2.5 million for Q2 2026.

• In Q2 2026, Share-based Compensation fell 78.57% year-over-year to $2.5 million; the TTM figure through Jun 2026 stood at $2.5 million (down 78.57% YoY), while the FY2025 annual figure was $18.6 million, up 154.79% from the prior year.
• Share-based Compensation came in at $2.5 million for Q2 2026 at Xilio Therapeutics, down from $2.8 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $11.5 million in Q3 2025 to a low of $1.5 million in Q4 2024.
• Average Share-based Compensation over 5 years is $5.7 million, with a median of $5.1 million recorded in 2022.
• Year-over-year, Share-based Compensation soared 523.22% in 2022 and slumped 78.57% in 2026.
• Over 5 years, Share-based Compensation stood at $1.8 million in 2022, then grew by 6.34% to $1.9 million in 2023, then declined by 21.45% to $1.5 million in 2024, then surged by 93.27% to $2.9 million in 2025, then fell by 16.22% to $2.5 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $2.5 million in Q2 2026, $2.8 million in Q1 2026, and $2.9 million in Q4 2025.